OrbiMed Reveals 8.9% Stake in BlossomHill Post-IPO, Alongside Board Influence and Registration Rights
BLSM is trading near its 52-week low of $15.96 (0.9% above the low).
Summary
OrbiMed Advisors disclosed an 8.9% stake in BlossomHill Therapeutics after the IPO, including board representation and registration rights, with shares locked up for 180 days.
Key Events · Ownership and Investor Activity · BLSM
-
OrbiMed Holds 8.9% Stake
OrbiMed Advisors and OrbiMed Capital GP VIII LLC beneficially own 2,714,279 shares (8.9%) of BlossomHill, based on 30,643,660 shares outstanding.
-
IPO Purchases and Conversions
Stake includes 1,039,996 Series A and 1,049,283 Series B preferred shares converted 1-for-1 at IPO, plus 625,000 shares bought at $16.00 in the IPO.
-
Board Representation
Carl L. Gordon, an OrbiMed member, serves on BlossomHill's board and must transfer any equity compensation to OrbiMed/OPI VIII.
-
Registration Rights and Lock-Up
OrbiMed holds demand, piggyback, and S-3 registration rights; shares are subject to a 180-day lock-up expiring in early February 2027.
Analysis · BLSM · Life Sciences
Following BlossomHill Therapeutics' August 10 IPO, pre-IPO backer OrbiMed Advisors now controls 2,714,279 shares, or 8.9% of the company. That position includes 1,039,996 Series A and 1,049,283 Series B preferred shares converted one-for-one at the offering, plus 625,000 shares acquired at $16.00. Board representation comes via Carl L. Gordon, an OrbiMed member, giving the firm a voice in governance. The filing also details registration rights and a 180-day lock-up, meaning OrbiMed cannot sell until early February 2027. While this is a notable ownership disclosure from a sophisticated healthcare investor, it largely consolidates previously reported IPO purchases.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLSM was trading at $16.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $493.4M. The 52-week trading range was $15.96 to $17.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.